fashion -WSS

fashion

author：knowledge 2025-09-30 15:15:29 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Diagnostic tests are hitting their mathematical limits

WSS

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

The EPA's new lead rule: How one expert crunched the numbers

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

30 years of 'Listening to Prozac'

hotspot

fashion

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

30 years of 'Listening to Prozac'

Continuity nursing helped my family in our darkest PICU moments

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Guidelines to prevent youth baseball injuries need more muscle

Fetal surgery at risk from Dobbs and new abortion restrictions

Novavax promises a turnaround & Lilly roils the obesity market

Rep. Raul Ruiz on the physician shortage and more

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Flagship Pioneering launches a new biotech in two countries

explore

With clinical trial data readouts, here's how to spot spin

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

30 years of 'Listening to Prozac'

CDC launches VaccineFinder tool to locate Covid

Disappointing trial forces Pfizer to pivot on obesity medicine plans

What don’t we know about an Alzheimer’s drug side effect?

explore

focus

leisure time

focus